vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Federal Realty Investment Trust (FRT). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $336.0M, roughly 1.5× Federal Realty Investment Trust). Federal Realty Investment Trust runs the higher net margin — 38.6% vs -10.1%, a 48.7% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 8.7%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 6.5%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Federal Realty Investment Trust is a real estate investment trust that invests in shopping centers in the Northeastern United States, the Mid-Atlantic states, California, and South Florida.

CLOV vs FRT — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.5× larger
CLOV
$487.7M
$336.0M
FRT
Growing faster (revenue YoY)
CLOV
CLOV
+36.0% gap
CLOV
44.7%
8.7%
FRT
Higher net margin
FRT
FRT
48.7% more per $
FRT
38.6%
-10.1%
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
6.5%
FRT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CLOV
CLOV
FRT
FRT
Revenue
$487.7M
$336.0M
Net Profit
$-49.3M
$129.7M
Gross Margin
Operating Margin
-10.1%
53.8%
Net Margin
-10.1%
38.6%
Revenue YoY
44.7%
8.7%
Net Profit YoY
-123.2%
103.5%
EPS (diluted)
$1.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
FRT
FRT
Q1 26
$336.0M
Q4 25
$487.7M
$336.0M
Q3 25
$496.6M
$322.3M
Q2 25
$477.6M
$311.5M
Q1 25
$462.3M
$309.2M
Q4 24
$337.0M
$311.4M
Q3 24
$331.0M
$303.6M
Q2 24
$356.3M
$296.1M
Net Profit
CLOV
CLOV
FRT
FRT
Q1 26
$129.7M
Q4 25
$-49.3M
$129.7M
Q3 25
$-24.4M
$61.6M
Q2 25
$-10.6M
$155.9M
Q1 25
$-1.3M
$63.8M
Q4 24
$-22.1M
$65.5M
Q3 24
$-9.2M
$61.0M
Q2 24
$7.4M
$112.0M
Gross Margin
CLOV
CLOV
FRT
FRT
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
24.5%
Q2 24
30.3%
Operating Margin
CLOV
CLOV
FRT
FRT
Q1 26
53.8%
Q4 25
-10.1%
53.8%
Q3 25
-4.9%
34.3%
Q2 25
-2.2%
65.1%
Q1 25
-0.3%
35.0%
Q4 24
-6.4%
35.1%
Q3 24
-2.7%
34.9%
Q2 24
2.0%
53.0%
Net Margin
CLOV
CLOV
FRT
FRT
Q1 26
38.6%
Q4 25
-10.1%
38.6%
Q3 25
-4.9%
19.1%
Q2 25
-2.2%
50.0%
Q1 25
-0.3%
20.6%
Q4 24
-6.6%
21.0%
Q3 24
-2.8%
20.1%
Q2 24
2.1%
37.8%
EPS (diluted)
CLOV
CLOV
FRT
FRT
Q1 26
$1.49
Q4 25
$1.49
Q3 25
$0.69
Q2 25
$1.78
Q1 25
$0.72
Q4 24
$0.74
Q3 24
$0.70
Q2 24
$1.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
FRT
FRT
Cash + ST InvestmentsLiquidity on hand
$78.3M
$107.4M
Total DebtLower is stronger
$5.0B
Stockholders' EquityBook value
$308.7M
$3.2B
Total Assets
$541.0M
$9.1B
Debt / EquityLower = less leverage
1.53×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
FRT
FRT
Q1 26
$107.4M
Q4 25
$78.3M
$107.4M
Q3 25
$111.3M
Q2 25
$177.0M
Q1 25
$109.2M
Q4 24
$194.5M
$123.4M
Q3 24
$288.0M
$97.0M
Q2 24
$254.8M
$103.2M
Total Debt
CLOV
CLOV
FRT
FRT
Q1 26
$5.0B
Q4 25
$5.0B
Q3 25
Q2 25
Q1 25
Q4 24
$4.5B
Q3 24
Q2 24
Stockholders' Equity
CLOV
CLOV
FRT
FRT
Q1 26
$3.2B
Q4 25
$308.7M
$3.2B
Q3 25
$340.9M
$3.2B
Q2 25
$344.2M
$3.2B
Q1 25
$336.1M
$3.2B
Q4 24
$341.1M
$3.2B
Q3 24
$342.2M
$3.1B
Q2 24
$324.9M
$3.0B
Total Assets
CLOV
CLOV
FRT
FRT
Q1 26
$9.1B
Q4 25
$541.0M
$9.1B
Q3 25
$559.7M
$8.9B
Q2 25
$575.0M
$8.6B
Q1 25
$583.7M
$8.6B
Q4 24
$580.7M
$8.5B
Q3 24
$653.0M
$8.5B
Q2 24
$674.2M
$8.4B
Debt / Equity
CLOV
CLOV
FRT
FRT
Q1 26
1.53×
Q4 25
1.53×
Q3 25
Q2 25
Q1 25
Q4 24
1.42×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
FRT
FRT
Operating Cash FlowLast quarter
$-66.9M
Free Cash FlowOCF − Capex
$-69.0M
FCF MarginFCF / Revenue
-14.1%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
FRT
FRT
Q1 26
Q4 25
$-66.9M
$622.4M
Q3 25
$12.1M
$147.8M
Q2 25
$5.4M
$150.7M
Q1 25
$-16.3M
$179.0M
Q4 24
$34.8M
$574.6M
Q3 24
$50.0M
$144.1M
Q2 24
$44.8M
$169.7M
Free Cash Flow
CLOV
CLOV
FRT
FRT
Q1 26
Q4 25
$-69.0M
Q3 25
$11.4M
Q2 25
$4.8M
Q1 25
$-16.5M
Q4 24
$33.3M
Q3 24
$49.6M
Q2 24
$44.4M
FCF Margin
CLOV
CLOV
FRT
FRT
Q1 26
Q4 25
-14.1%
Q3 25
2.3%
Q2 25
1.0%
Q1 25
-3.6%
Q4 24
9.9%
Q3 24
15.0%
Q2 24
12.5%
Capex Intensity
CLOV
CLOV
FRT
FRT
Q1 26
Q4 25
0.4%
Q3 25
0.1%
Q2 25
0.1%
Q1 25
0.0%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.1%
Cash Conversion
CLOV
CLOV
FRT
FRT
Q1 26
Q4 25
4.80×
Q3 25
2.40×
Q2 25
0.97×
Q1 25
2.81×
Q4 24
8.77×
Q3 24
2.36×
Q2 24
6.04×
1.52×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons